News
NWBO
0.501
+0.22%
0.001
Weekly Report: what happened at NWBO last week (0408-0412)?
Weekly Report · 3d ago
Weekly Report: what happened at NWBO last week (0401-0405)?
Weekly Report · 04/08 12:23
Weekly Report: what happened at NWBO last week (0325-0329)?
Weekly Report · 04/01 12:20
Weekly Report: what happened at NWBO last week (0318-0322)?
Weekly Report · 03/25 12:23
Northwest Biotherapeutics Appoints Pat Sarma as Class II Director
TipRanks · 03/22 20:42
Press Release: Northwest Biotherapeutics Appoints Seasoned Business Executive and Investor To Its Board of Directors
Northwest Biotherapeutics Appoints Pat Sarma to its Board of Directors effective March 18, 2024. Sarma is a business executive and investor with decades of experience. He founded and built a company known for developing the AMI firmware for PC compatibility. Northwest Bio is a biotechnology company developing personalized immune therapies for solid tumor cancers.
Dow Jones · 03/21 15:09
Weekly Report: what happened at NWBO last week (0311-0315)?
Weekly Report · 03/18 12:21
Northwest Biotherapeutics Board Veteran Jasinowski Retires
TipRanks · 03/14 20:44
Weekly Report: what happened at NWBO last week (0304-0308)?
Weekly Report · 03/11 12:16
Weekly Report: what happened at NWBO last week (0226-0301)?
Weekly Report · 03/04 12:21
Weekly Report: what happened at NWBO last week (0219-0223)?
Weekly Report · 02/26 12:41
Weekly Report: what happened at NWBO last week (0212-0216)?
Weekly Report · 02/19 12:43
Weekly Report: what happened at NWBO last week (0205-0209)?
Weekly Report · 02/12 12:27
Northwest Biotherapeutics Moves From Optimization of Flaskworks Prototype to Fabrication of GMP-Compliant Units For Installation, Validation and Final Testing Prior to Regulatory Certification
Northwest Biotherapeutics announces key development work for the flaskworks manufacturing system has been completed. The company is developing a system to manufacture DCVax® personalized immune therapies for solid tumor cancers. The patent coverage of the Flaskworks system has also been expanded. The Company believes the system will play a central role in enabling the efficient scale-up of manufacturing.
PR Newswire · 02/06 14:30
Weekly Report: what happened at NWBO last week (0129-0202)?
Weekly Report · 02/05 12:41
Weekly Report: what happened at NWBO last week (0122-0126)?
Weekly Report · 01/29 12:22
Weekly Report: what happened at NWBO last week (0115-0119)?
Weekly Report · 01/22 12:29
Weekly Report: what happened at NWBO last week (0108-0112)?
Weekly Report · 01/15 12:23
Weekly Report: what happened at NWBO last week (0101-0105)?
Weekly Report · 01/08 12:29
Weekly Report: what happened at NWBO last week (1225-1229)?
Weekly Report · 01/01 12:20
More
Webull provides a variety of real-time NWBO stock news. You can receive the latest news about Northwest Bio through multiple platforms. This information may help you make smarter investment decisions.
About NWBO
Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing immunotherapy products to treat cancer. One of the product lines (DCVax-L) is designed to cover all solid tumor cancers in which the tumors can be surgically removed. Another product line (DCVax-Direct) is designed for all solid tumor cancers. The Company's lead product, DCVax-L, is in an ongoing Phase III trial for diagnosed Glioblastome multiforme (GBM), with over 60 trial sites. Its second product, DCVax-Direct, is being studied in a 60-patient Phase I/II trial for all types of inoperable solid tumors. The 40-patient Phase I stage of the trial has been completed. The Company is working on preparations for Phase II trials of DCVax-Direct. The Company's platform technology, DCVax, uses activated dendritic cells to mobilize a patient's own immune system, including T cells, B cells and antibodies and natural killer cells, among others to attack cancer cells to attack their cancer.